Fresh analysis reveals that individuals who come off new weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Published data in a major medical journal points out that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be informed of the risk of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of recovery means a return to starting mass in about 18 months.
Comparing Approaches
The study, which examined dozens of studies involving thousands of participants, compared the outcomes of the injectable medications with other pills.
Scientists note that individuals who lose weight through lifestyle changes alone generally experience a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Fast Rebound
Nutrition scientists propose the mechanism of the drugs accounts for the accelerated regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts contend that, considering the high risk of relapse, the therapy is often life-long.
This opinion is supported by drug manufacturers, who say that the findings "underscore the chronic nature of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
People who have stopped the medication describe a sudden return of hunger.
"It was like a switch activating and you're instantly extremely hungry," described a patient.
The struggle is compounded if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Significant Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, experts stress that while the jabs are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural support.